Mabpharm (HKSE:02181) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Jun. 08, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Mabpharm's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Mabpharm's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Mabpharm's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabpharm's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Mabpharm's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Mabpharm (HKSE:02181) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Mabpharm EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Mabpharm's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines